Mutant forms of kinin B 1 receptor (B 1 R) and analogs of the full agonist des-Arg 9 -bradykinin (DABK) were investigated aiming to verify the importance of selected receptor residues and of each agonist-peptide residue in the specific binding and activation. and Cys100Ser mutated B 1 R receptors. The results obtained suggested that the same bimodal scheme adopted for AngII-AT 1 R system may be applied to DABK binding to B 1 R. The most crucial similarity in the two cases is that the N t segments of peptides equally bind to the homologous Asp 712 residue of both AT 1 R and B 1 R extracellular sites. Confirming this preliminary supposition, mutation of residues located at the B 1 R extracellular site as EC3 loop Asp 712 and Cys 100 caused the same modifications in biological assays observed in AT 1 R submitted to homologous mutations, such as significant weakening of agonist binding and reduction of post-receptor-activation processes. These findings provided enough support for defining a site that determines the specific binding of DABK to B 1 R receptors.
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Introduction
Des-Arg 9 -bradykinin (DABK) 2 is the regular agonist of kinin B 1 receptor (B 1 R), a member of family A G-protein-coupled receptors (AGPCRs) [1] . As the structure of all these receptors, B 1 R consists of a seven transmembrane-helix bundle (7TM), linked to extracellular N-terminal (N t ) and cytosolic C-terminal (C t ) segments, with the seven helices alternately connected by three extracellular (EC) and three cytosolic (IC) loops [2] . At the present time, as most of the AGPCR sequences are known, a conserved motif has been recognized in all types of angiotensin II (AngII), bradykinin (BK), endothelin, chemokine, purine and Cysleukotriene receptors and some types of neuropeptide receptors, consisting of an insertion of 8-10 residues in the middle of EC3 loop, including a conserved residue of Cys 650 supposedly making a disulfide bond with a second conserved Cys 100 residue located at the N t segment (Figs. 1 and 2), [3] . This pattern was then investigated for function, especially in AT 1 R receptors, thus revealing that the AngII N-terminal segment (Asp 1 and Arg 2 residues) binds to receptor EC3 loop and N t segment residues [4] [5] [6] [7] [8] leading the conserved motif to be classified as an extracellular sub-site for agonist binding [9] . Regarding B 1 R receptors, binding patterns of DABK seem to be similar to those observed in AngII interaction with AT 1 R. (1) The agonist C t carboxylate group is stabilized by electrostatic contacts with helix III Lys 323 [10] and helix V Arg 508 [11] both at the external half of the receptor 7TM central cavity. (2) The residues in the external segment of the kinin receptors' helix VI appear to be linked to high-affinity binding [10] . (3) The agonist N-terminal R 1 residue binds to receptor residues located at the other side of the 7TM structure as EC3 loop Asp 712 (and Glu 709 ) [12] . The homology of binding between B 1 R and AT 1 R is assumed because Asp 712 residue of the former receptor corresponds to the Asp 712 residue of AT 1 R extracellular site at which the AngII Arg 2 residue is supposed to bind [6] .
In the current work, B 1 R and DABK or analogs are studied aiming to ascertain the importance of some receptor residues and each agonist residue for specific binding, production of IP 3 [3, 7] . As AngII, DABK also displays an Arg residue at its N t segment and thus it might be postulated that B 1 R extracellular site could play the same role observed with AT 1 R, upon binding its specific agonist. Herein this possibility was confirmed from experimental results obtained by binding DABK and analogs to Asp712Ala and Cys100Ser mutants' forms of B 1 R.
Material and methods

Peptides synthesis
The peptides were synthesized manually in accordance with the standard tert-butyloxycarbonil (Boc) protocol [13, 14] . In the Boc chemistry, after coupling the C t amino acid to the resin, the successive α-amino group deprotection and neutralization steps were performed in 30% TFA (trifluoroacetic acid)/DCM (dichloromethane) (30 min) and 10% TEA (triethylamine)/DCM (10 min). The amino acids were coupled with 3-fold excess, using DIC (N,N′-diisopropylcarbodiimide)/HOBt (1-hydroxybenzotriazole) in DMF (N,N-dimethylformamide). After a 3 h coupling period, the qualitative ninhydrin test was performed to estimate the completeness of the reaction. To check the purity of the synthesized peptide sequence attached to the resin, cleavage reactions with small aliquots of resin were carried out in anhydrous HF, at 0°C for 2 h. Analytical HPLC (High performance liquid chromatography), as well as LC/ESI-M (Liquid chromatography/Electrospray ionization -mass spectrometry) and amino acid analysis were used to check the homogeneity of each synthesized resin-bound peptide sequence. The synthesized analogs are presented in Table 1 .
Biological activities of the peptides
Experiments were carried out with C57BL/6J mice from the Centro de Desenvolvimento de Modelos Experimentais da Universidade Federal de São Paulo (CEDEME-UNIFESP). The animals were maintained on standard mouse chow at 21-23°C and kept on 12 h light:12 h dark cycle and allowed ad libitum access to food and water. After 12-16 weeks, old mice weighing 26-30 g were sacrificed by cervical dislocation and exsanguination. This study was in accordance with current guidelines for the care of laboratory animals and ethical guidelines for investigations approved by the Animal Care Committee of UNIFESP.
All experiments to assess the biological activities of the new peptides were performed in the mouse stomach, which contains functional B 2 and B 1 receptors. The stomach fundus isolated from mouse has been reported to respond to the agonists BK and DABK [15, 16] The residue positions were numbered according to GPCRDB system. Segments of sequences belonging to a same secondary structure (alpha-helix or beta structure) have a referential 3-digit number: the first digit designates the number of helix (1-8 for helices I-VIII) and other intermediate secondary structures; the second and third digits form a number that defines a certain position in the respective segment. Thus, different positions are numbered according to the segments at which they are located and the distance from the respective referentials. and quantitative RT-PCR analysis of B 1 and B 2 mRNA expression was described by [17] in this tissue. Stomach fundus was isolated from mouse, divided in two strips of the longitudinal muscle and mounted into a 5 ml organ baths (Panlab s.l., Cornella, CA, Spain), containing modified Krebs-Ringer solution: 144 mM NaCl, 5 mM KCl, 1.1 mM MgSO 4 , 25 mM NaHCO 3 , 1.1 mM NaH 2 PO 4 , 1.25 mM CaCl and 5.5 mM glucose at 37°C (pH 7.4) continuously carboxygenated (95% O 2 /5% CO 2 ). Contractile responses to the stimulations with DABK and its analogs were recorded. The resting tension was maintained at 0.5 g and the tissues were left to equilibrate for 90 min, with frequent changing of fresh bathing solution. Following, changes in tension produced by the stimulants were measured with a tension transducer TRI201 (Panlab s.l., Cornella, CA, Spain), through an amplifier Powerlab 4/30 and software Labchart Pro V7 (ADInstruments, Colorado Springs, CO, USA).
Cumulative concentration-contractile response curves were constructed for DABK and analogs, by applying increasing concentrations (0.1 nM to 1 μM) of each agonist to determine the apparent affinity of agonists in terms of pD 2 (the negative logarithm of the concentration of agonist that produces 50% of the maximal effect, EC 50 ) and the maximal effect (E max ) was calculated in relation to the effect of 140 mM KCl, which was considered 100%. The curve-fitting analysis for doseresponse curves was performed using the GraphPad-Prism 3.0 Program (GraphPad Software, San Diego, CA, US).
Construction of kinin B 1 R mutants
The vector pEYFP-N 1 B 1 R (Clontech Laboratories, Mountain View, CA, US) expressing rat B 1 R was gently donated by Santos et al. [11] and used as a template for the mutant Asp712Ala, replacing the Asp 712 with Ala and Cys100Ser, replacing the Cys 100 with Ser. The site-directed mutagenesis was performed with QuickChange site-directed mutagenesis kit (Stratagene, Santa Clara, CA, US) according to the manufacturer's instructions. The mutagenesis oligonucleotides used are listed below. For a single Asp712Ala mutant (sense, 5′-GAAGGAGATCACAGCCCTGGGCC TGCAGC-3′ and antisense, 5′-GCTGCAGGCCCAGGGCTGTGATCTCCTTC-3′). Cys100Ser mutant (sense, 5′-GCCAACATTACCTCCAGCGAGAGTGC CCTA-3′ and antisense, 5′-TAGGGCACTCTCGCTGGAGGTAATGTTGGC-3′). All receptor constructs were initially identified by the presence of a diagnostic restriction site and subsequently verified by sequencing.
Cell culture and transfection
Chinese hamster ovary (CHO) cells were cultured in Dulbecco's modified Eagle's medium -DMEM (Invitrogen, Carlsbad, CA, US) supplemented with 10% of fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM glutamine (all from Invitrogen, Carlsbad, CA, US). Cultures were maintained at 37°C in a humidified 5% CO 2 atm. Expression plasmids containing wild-type receptor and B 1 R mutated receptors, Asp712Ala and Cys100Ser, were permanently transfected into CHO cells by lipofectamine 2000 (Invitrogen, Carlsbad, CA, US), method according to the manufacturer's instructions and 2 μg of plasmid DNA for each sample. For the establishment of stable cell lines, transfected cultures were maintained in culture medium supplemented with 750 μg of G-418 (Invitrogen, Carlsbad, CA, US).
Expression of kinin B 1 R and mutants in transfected CHO cells
Clones with high expression levels of wild-type B 1 R mRNA and of mutated receptors were selected by real-time PCR. CHO cells transfected with the wild-type receptor and mutants were seeded at 1 × 10 6 cells per well in 6-well plates and left for 24 h at 37°C.
The culture medium was siphoned off and the total RNA was isolated using TRIzol® reagent (Invitrogen, Carlsbad, CA, US), according to the manufacturer's instructions. After purification, the presence of intact RNA was verified on an ethidium bromide-stained agarose gel and the total RNA was submitted to reverse transcription using SuperScript™ III First-Strand reverse transcriptase kit (Invitrogen, Carlsbad, CA, US).
To determine the expression of B 1 R, real-time PCR was performed with 5 μl of 1:10 dilution cDNA samples pre-obtained, where each reaction was carried out using Taqman Universal PCR Master Mix (Applied Biosystems, Foster City, CA, US), according to the manufacturer's instructions. Primers used for real-time PCR were as follows: murine β-actin (GenBank accession no. NM007393), forward primer 5′-CTGG CCTCACTGTCCACCTT-3′ and reverse primer 5′-CGGACTCATCGTACTC CTGCTT-3′; and probe. 5′-6FAM-CTGATCCACATCTGCT-TAMRA-3′ and rat B 1 R (GenBank accession no. NM030851), reverse primer 5′-CAA ACAGGTTGGCCTTGATGAC-3′, forward primer 5′-CTGGCCCTTCGGAAC TGA-3′ and probe 5′-6FAM-CCCGCTGACCACCC-TAMRA-3′. The real-time PCRs were performed with an ABI PRISM® 7000 sequence detection system (Applied Biosystems, Foster City, CA, US) and cycle conditions were: 50°C for 2 min, 95°C for 10 min, followed by 50 cycles of 95°C for 15 s (melting step), 60°C for 1 min (anneal/ extend step). Increases in the amount of reporter dye fluorescence during the 50 amplification cycles were monitored using Sequence Detector software (SDS version 1.6, Applied Biosystems, Foster City, CA, US). Quantification of the target amount was performed by measuring the threshold cycle, C T , which is defined as the fractional cycle number at which the fluorescence encounters a fixed threshold. A normalized value to evaluate the mRNA expression was calculated as the difference in the threshold cycle: the C T values of receptor minus C T of internal standard (β-actin), resulting in ΔC T . Since it is uncommon to use ΔC T parameter as a relative expression parameter due to this logarithmic characteristic, the 2 −ΔCT parameter was used to express the relative gene expression data [18] . B 1 R mRNA abundance was quantified as a relative value compared with an internal reference, β-actin, of which the abundance was assumed not to change between the varying experimental conditions.
Heterologous competition binding assay
The Table 1 ) for competition binding assays. The plates were incubated overnight at 4°C. The binding buffer was siphoned off and the cells were washed twice with cold wash buffer and then lysed with lysis buffer (0.5% SDS and 0.1 mol/l NaOH). Receptor-bound radiolabels were counted to determine inhibition Peptide amino acids are expressed by the one-letter code. A=alanine, R=arginine, P = proline, G = glycine, F = phenylalanine, S = serine, K = lysine. under the same protocol described above. The DABK (100 nM) induced effect was tested in the presence and absence of 1 μM R-715, a specific antagonist of B 1 R, pre-incubated for 30 min. The fluorescence polarization was detected by Victor X5 microplate reader (Perkin-Elmer, Waltham, MA, US). The data were acquired in triplicate to draw the dose-response curves using the GraphPad 3.0 Program (GraphPad Software, San Diego, CA, US).
Calcium assay
The ] i levels. The calcium measurements were performed using Fluo4 NW Calcium Assay kit (Molecular Probes, Eugene, OR, US).
One dose of the peptide was added into each well and the results were used to draw the sigmoidal dose-response curve. At the end of each experiment 1 μM ionomycin (a Ca 2+ ionophore) was administered to expose the cytosolic Fluo-4NW to the free extracellular Ca 2+ to get the maximal fluorescence signal (added F max ) and 5 mM of EGTA (ethylene glycol tetraacetic acid) was to chelate all free Ca 2+ in order to get the minimum signal, equivalent to the cell autofluorescence value (F min ).
The Ca 2+ intracellular concentration [Ca 2+ ] i was calculated using the following formula (Grynkiewicz et al., 1985) . 
Modeling procedure for angiotensin and kinin receptors
Based on sequence alignments of Fig. 1 , angiotensin II type I and kinin B 1 receptors were built by homology via the WHAT IF program [19] , to the CXCR4 receptor, the first AGPCR possessing sequence features resembling the extracellular site, for which a high-resolution 3D structure has been determined [20] .
Statistical analysis
All data are shown as mean ± S.D. (n), number of experiments. Statistical analyses were performed using two-way ANOVA followed by post-test Bonferroni. For statistical comparison, 95% confidence intervals were used.
Results
Biological activity of DABK and analogs
The biological activity of DABK and analogs mediated by B 1 R (Table 1) was measured by parameters of apparent affinity (pD 2 ) and E max (Table 2 ) through mechanical recordings of the contractile responses of stomach fundus isolated from mouse. Affinity was kept at wild-agonist level by A 6 -DABK (compound 7); it was slightly increased for K 1 -DABK (compound 11); it was slightly reduced for can replace Arg; Lys added at the position 0 reduced the binding. At the position 4, the presence of any residue instead of Gly is deleterious for binding. E max values produced by different analogs of DABK varied from 27% to 97% whereas that value for the control DABK was 59% (Table 2) . 
B 1 R and mutant expression in transfected CHO cells
CHO cells were permanently transfected with the plasmid containing the coding region for the wild-type rat B 1 R and the coding region for B 1 R carrying the proposed mutations and with an empty plasmid (mock cells). The expression of the B 1 R gene in these cells was evaluated by real-time PCR, by radioligand binding studies and by a functional assay on the IP 3 production and changes in intracellular calcium concentration in response to B 1 R agonist, DABK (Fig. 3) . Fig. 3A shows the mRNA expression of cell clones expressing the B 1 R and mutants selected, with high and comparable levels between them. In the binding study, cells expressing only the B 1 R receptor or B 1 R mutants were able to bind specifically the B 1 R agonist with high affinity, whereas mock cells displayed no binding for the agonist (Fig. 3B ). Furthermore, DABK was able to elicit a concentrationresponse effect on the IP3 production in CHO cells expressing the B 1 R or mutant receptor but not in mock cells (Fig. 3C ). This effect was inhibited by the specific B 1 R antagonist R-715, showing the expression of a functional membrane receptor (Fig. 3D) .
Parameters for interaction between B 1 R and DABK or analogs
Data from binding assays, the IC 50 value for binding affinity of DABK analogs to B 1 R was about 3 nM (Table 3) , whereas EC 50 for production of IP 3 and increase of cytoplasmic calcium was 6 and 4 nM (Tables 4  and 5 ) respectively. The dependence of IC 50 values for binding affinity, EC 50 for IP 3 formation and increase of intracellular calcium, on the modified residues of DABK followed the same pattern observed with biological activity results (Table 2) . Also in agreement with biological activity results, E max values for the three analyses were little impaired being rather independent of residue modifications.
The crucial positions for DABK binding were R 
Parameters for interaction of Asp712Ala mutated B 1 R and DABK analogs
Parameters for interaction of DABK and its analogs with the mutant Asp712Ala were drastically modified in relation to those observed for the wild receptor. In fact, IC 50 values varied from 3 to 370 nM for binding affinity (Table 3) , for EC 50 values from 6 to 360 nM for IP 3 formation (Table 4) and from 4 to 192 nM for calcium mobilization to B 1 R (Table 5 ). E max values for the three parameters were not correlated to the several amino acids residues of the analogs (Tables 3-5) .
Bindings of DABK analogs to the mutated receptor were shown to be weaker than those of the same analogs to wild receptor but keeping the same profile, except for the R 1 residue. (Tables 4 and 5 ).
Parameters for interaction of Cys100Ser mutated B 1 R and DABK analogs
Absence of the second disulfide bond in Cys100Ser mutated B 1 R caused a deleterious effect on the binding affinity of A (Table 3 ). The profile for changes was quite similar to that produced by Asp712Ala mutant receptor. However the increases in EC 50 values were lower than those observed with wild receptor. Effects on IP 3 formation and calcium mobilization followed a same profile (Tables 4 and 5 ). Thus it is plausible to associate the two mutations to a same effect on the receptor leading to the modification of the extracellular site structure. A fact remaining to be explained is why the binding of F 8 -DABK analog was so reduced upon receptor Cys 650 mutation by the same rate that observed for the Asp712Ala mutant, (Table 3) . [21] . R 1 certainly is the main bindinginvolved residue, at least at the N t side of the peptide by acting through its positive charge which can be perfectly replaced by Lys (Table 3 ) without loss of binding affinity. In the extreme ends of DABK, other complex mechanisms than those dependent on the type of residue side-chain, ought to be considered in order to explain the effects observed.
In the C t side, the DABK F 8 side-chain seems to be decisive for peptide binding and activity-triggering as denoted by the values in Tables 2-5 but it might also be accessory considering the importance of the special binding of the C t carboxylate with the helix III Lys 323 [10] and helix V Arg 508 [11] residues at the external half of receptor 7TM central cavity. This association makes DABK the full-agonist of B 1 R receptor whereas kinin B 2 receptor is able to bind BK since it contains an additional locus located one position ahead of its structure to bind the residue R 9 of this peptide.
Binding of N t segment of DABK to kinin B 1 R still seems to display a dependence on residues that are occupying positions-2, -1 and -0, preceding the positions 1-8 of the peptide itself. For instance, the presence of K 0 , as in kallidins, impairs the binding and activity of rat or mouse B 1 R a little but considerably affects the same properties of these receptors coming from other species as man, rabbit, cow and others. No explanation has been available yet in order to explain this difference [22] .
Factors regulating DABK binding to the kinin B 1 receptor
A specific salt bridge between the DABK R 1 side-chain and B 1 R Asp 712 seems to be the basic component for a wild-type binding mode involving peptide and receptor [12] . As an indication of this condition, IC 50 values of 3 nM or 152 nM are found for complexes between the wild-type receptor and DABK or A 1 -DABK in which the bond is present or not, respectively (first and second lines of the first IC 50 data column in Table 3 On the other side, if the specific salt bridge is eliminated upon an Asp712Ala mutation in the B 1 R, other event leading to weakening of the peptide binding seems to take place. This is indicated by IC 50 values shown in the middle IC 50 data column ( ), [12] . The present picture allows us to point out to a very plausible condition in which the molecule of bound-agonist is shown as a U-shaped figure (Fig. 4) . The first arm of this figure is linked to the receptor extracellular site via R 1 -Asp 712 bridge. The interaction of the second arm consists of two components, the first one represented by the binding of the C t peptide residue F 8 to a very conserved receptor aromatic-ring cluster and the second one by the binding of the peptide C t carboxylate to the positive side-chains of helix III Lys 323 [10] and helix V Arg 508 [11] . The apparently non-bonded peptide F 5 , S 6 and P 7 residues is distributed over the bend of the horseshoe, a condition that is consistent since these residues are not important for peptide activity (Table 2) , binding (Table 3 ) and participation in post-activation events as IP 3 formation and calcium mobilization (Tables 4 and 5 ).
Concluding remarks
In short, experimental data of the current work could emphasize some remarkable points about the interaction mode of DABK to B 1 R.
(1) The residues of F 5 , H 6 and P
7
, devoid of importance for biological activity, agonist binding and post-activation events, are in the middle of the peptide sequence.
(2) A model of B 1 R built from chemokine CXCR 4 receptor, shows that, in order to fulfill all interactions suggested by previous mutagenesis studies, DABK has to exhibit a U-shaped configuration so that its extremes are bound to two distinct but close regions of the receptor (Fig. 4) and its middle bend is probably in a non-bonded condition. (3) This scheme indicates that the interaction of DABK with B 1 R is bimodal. The N t extreme of the peptide binds at the extracellular site of receptor whereas the C t extreme binds at a locus flanked by the extracellular halves of helices III, V and VI. (4) Modifications carried out on the extracellular site of B 1 R as Asp712Ala and Cys100Ser mutations, reduced the binding of DABK analogs to these mutated receptors and the activity elicited by this binding, by a process that followed the same profile previously observed with binding of DABK analogs to wild receptor. That is, for both wild and mutated receptors structural modifications were more deleterious for binding of peptide analogs when residues were changed at both extremes than at the middle of the peptide sequences. This fact would require that Asp712Ala and Cys100Ser mutations should induce equally modifications on the other side of the receptor structure, namely at the subsite for binding DABK C t F 8 residue and C-carboxylate as widely shown in Tables 3-5 . In general, the symmetrical distribution of modifications induced on B 1 R structure would have a unique development: structure of receptor may be modified by residue mutations but the U-shaped configuration of DABK forming an overall complex with the receptor is kept unchanged.
